New hope for tough breast cancer: experimental drug trial seeks to slow disease
NCT ID NCT07299409
Summary
This study is testing whether the drug sacituzumab govitecan can slow cancer progression when used as the first treatment for adults with advanced triple-negative breast cancer. Researchers will give the drug to 24 participants and track how well their cancer responds, comparing results between different genetic subtypes of the disease. The trial will also monitor side effects and quality of life while patients receive treatment every 21 days until their cancer worsens or they choose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Vancouver Center
Vancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.